IL-1β Inhibition Is Associated with Reduced Tumor Growth and Changes in Anti-Tumor Immunity and the Colonic Microbiome
International Journal of Molecular Sciences · 20.11.2026 · 27 (22) · 10471
DOI: 10.3390/ijms272210471 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 20.11.2026. Verfasst von Noy Machluf-Katz und 16 weiteren Autor:innen. Die Arbeit nennt 57 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: German Cancer Research Center, Israeli Ministry of Innovation, Science and Technology.
Abstract (Originalsprache)
Colorectal cancer (CRC) is a leading cause of cancer mortality worldwide. Interleukin-1β (IL-1β) is a pro-inflammatory cytokine upregulated in many tumors, including CRC. In the tumor microenvironment (TME) it promotes angiogenesis, immunosuppression, and resistance to chemotherapy. We aimed to elucidate the correlation between TME IL-1β and colon microbiotic changes during CRC progression and approach inhibition of IL-1β in combination with standard chemotherapy as a therapeutic strategy. Using an orthotopic mouse model of CRC, we compared tumor growth, metastatic spread, immune infiltration and microbiome composition in control and IL-1β knockout mice. We studied the effects of IL-1β neutralization in combination with FOLFOX chemotherapy on CRC progression. IL-1β promotes CRC progression by enhancing pro-inflammatory signaling, associated with recruiting myeloid cells and microbiome dysbiosis. Its deficiency delayed tumor growth and reduced metastasis that was accompanied by increased infiltration of antigen-presenting cells and changes in gut microbiota. FOLFOX chemotherapy exacerbated systemic and local inflammation, facilitating liver metastasis, where the addition of anti-IL-1β antibodies significantly reduced FOLFOX-induced inflammation and enhanced anti-tumor immunity. IL-1β from the TME links microbiome dysbiosis, tumor-promoting inflammation and poor chemotherapy outcomes in CRC. Combining IL-1β inhibition with standard FOLFOX chemotherapy represents a promising therapeutic approach to CRC treatment.
Förderung
- German Cancer Research Center
- Israeli Ministry of Innovation, Science and Technology
Zitieren
APA
Machluf-Katz, N., Barsky, G., Stalin, S., Moadi, L., Weiner, A., Goldstein, O., Krishnamohan, M., Kaplanov, I., Fishman, D., Bersudsky, M., Braiman, A., Levin, L., Cooks, T., Turjeman, S., Koren, O., Osyntsov, A., & Voronov, E. (2026). IL-1β Inhibition Is Associated with Reduced Tumor Growth and Changes in Anti-Tumor Immunity and the Colonic Microbiome. International Journal of Molecular Sciences, 27(22), 10471. https://doi.org/10.3390/ijms272210471
Vancouver
Machluf-Katz N, Barsky G, Stalin S, Moadi L, Weiner A, Goldstein O, et al. IL-1β Inhibition Is Associated with Reduced Tumor Growth and Changes in Anti-Tumor Immunity and the Colonic Microbiome. International Journal of Molecular Sciences. 2026;27(22):10471. doi:10.3390/ijms272210471
BibTeX
@article{MachlufKatz2026,
author = {Machluf-Katz, Noy and Barsky, Guy and Stalin, Sami and Moadi, Lelyan and Weiner, Ariel and Goldstein, Oron and Krishnamohan, Mathumathi and Kaplanov, Irena and Fishman, Daniel and Bersudsky, Marina and Braiman, Alex and Levin, Liron and Cooks, Tomer and Turjeman, Sondra and Koren, Omry and Osyntsov, Anton and Voronov, Elena},
title = {IL-1β Inhibition Is Associated with Reduced Tumor Growth and Changes in Anti-Tumor Immunity and the Colonic Microbiome},
journal = {International Journal of Molecular Sciences},
year = {2026},
volume = {27},
number = {22},
pages = {10471},
doi = {10.3390/ijms272210471}
}
EUVIMED